The Management of Data for the Banking, Qualification, and Distribution of Induced Pluripotent Stem Cells: Lessons Learned from the European Bank for Induced Pluripotent Stem Cells

Author:

Mah Nancy1ORCID,Kurtz Andreas12,Fuhr Antonie1ORCID,Seltmann Stefanie1,Chen Ying1,Bultjer Nils1,Dewender Johannes1,Lual Ayuen3,Steeg Rachel4ORCID,Mueller Sabine C.1ORCID

Affiliation:

1. Fraunhofer-Institute für Biomedizinische Technik (IBMT), Joseph-von-Fraunhofer Weg 1, 66280 Sulzbach, Germany

2. Berlin Institute of Health Center for Regenerative Therapies, Augustenburger Platz 1, 13353 Berlin, Germany

3. European Collection of Authenticated Cell Cultures (ECACC), UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK

4. Fraunhofer UK Research Ltd., Technology and Innovation Centre, 99 George St., Glasgow G1 1RD, UK

Abstract

The European Bank for induced pluripotent Stem Cells (EBiSC) was established in 2014 as a non-profit project for the banking, quality control, and distribution of human iPSC lines for research around the world. EBiSC iPSCs are deposited from diverse laboratories internationally and, hence, a key activity for EBiSC is standardising not only the iPSC lines themselves but also the data associated with them. This includes enabling unique nomenclature for the cells, as well as applying uniformity to the data provided by the cell line generator versus quality control data generated by EBiSC, and providing mechanisms to share personal data in a secure and GDPR-compliant manner. A joint approach implemented by EBiSC and the human pluripotent stem cell registry (hPSCreg®) has provided a solution that enabled hPSCreg® to improve its registration platform for iPSCs and EBiSC to have a pipeline for the import, standardisation, storage, and management of data associated with EBiSC iPSCs. In this work, we describe the experience of cell line data management for iPSC banking throughout the course of EBiSC’s development as a central European banking infrastructure and present a model for how this could be implemented by other iPSC repositories to increase the FAIRness of iPSC research globally.

Funder

Innovative Medicines Initiative

Innovative Medicines Initiative 2

Publisher

MDPI AG

Subject

General Medicine

Reference27 articles.

1. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors;Takahashi;Cell,2006

2. Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies;Kim;NPJ Regen. Med.,2022

3. (2023, January 05). Under Development: Biotechnology—Data Interoperability for Stem Cell Data—Part 1: Framework. Available online: https://www.iso.org/standard/83185.html.

4. (2022, September 05). International Society for Stem Cell Research Guidelines for Stem Cell Research and Clinical Translation 2021. Available online: https://www.isscr.org/s/isscr-guidelines-for-stem-cell-research-and-clinical-translation-2021.pdf.

5. First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine;Sakurai;Stem Cells Transl. Med.,2016

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3